Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three intravenous anesthetic agents—propofol, midazolam, and remifentanil—used together for induction and maintenance of general anesthesia or deep sedation. Propofol is a sedative-hypnotic that acts as a positive allosteric modulator at GABA-A receptors, producing rapid onset hypnosis. Midazolam is a benzodiazepine that also enhances GABAergic inhibition via GABA-A receptors, providing anxiolysis, amnesia, and additional sedation. Remifentanil is an ultra-short-acting synthetic opioid agonist at the mu-opioid receptor (OPRM1), providing potent analgesia with rapid onset and offset. The combination allows for synergistic effects in anesthesia induction and maintenance; using all three drugs can reduce the required dose of each agent while achieving effective hypnosis, amnesia, analgesia, and muscle relaxation[5][7]. This regimen is commonly used in surgical settings to optimize patient comfort and safety during procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propofol + midazolam + remifentanil.